The short answer is no, we will not have a high-throughput routine clinical test for cell-mediated immunity like the antibody test.
(Disclaimer - I’m not a expert in this specific field, but I have some knowledge of it.)
Antibodies recognize viral proteins in their natural state, and antibodies are small. So the antibody test immobilizes viral protein antigen on a surface, then any antibodies in the patient sample that are specific to the viral protein antigen will stick to that surface where they can be detected. (Google ELISA test for more detail)
Unlike antibodies, T-cell receptors recognize processed segments of viral protein in complex with MHC molecules, for interesting reasons that I talked about here:
So, there are two challenges. First, the thing that T-cell receptors recognize is significantly more complex than just a viral protein in its raw state, so you have to make that, and you also have to label it with a fluorescent tag because of the second problem… You’re looking for cells, which are much larger than antibodies and cannot be immobilized on a surface in the same way. I’m not aware of any T-cell assay that does not involve flow cytometry, a much more complex experimental technique.
The fact that these experimental techniques are more difficult is the reason that it’s taken time to produce this research on cell-mediated immunity.